VACCINE TYPE

• Three COVID-19 vaccines are commercially available for use. The CDC does not recommend one particular product over another.
  • The Pfizer-BioNTech vaccine is a lipid nanoparticle-formulated, nucleoside-modified RNA (mRNA) vaccine encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 spike protein.
  • The Moderna COVID-19 vaccine (mRNA-1273) is a lipid nanoparticle-encapsulated, nucleoside-modified messenger RNA vaccine that encodes the SARS-CoV-2 spike glycoprotein.
  • The Novavax COVID-19 vaccine (NVX-CoV2373) is an adjuvanted vaccine containing purified, full-length rS protein. The vaccine elicits an immune response to this protein, leading to protection against COVID-19.
• Current recommendations call for ’updated’ vaccines, including the 2024-25 COVID-19 vaccines.
  • These updated vaccines closely target the XBB lineage of the Omicron variant and may restore protection against severe COVID-19 that may have waned over time.
  • As of August 22, 2024, the 2024-25 updated vaccines from Pfizer-BioNTech and Moderna were available.
  • As of August 30, 2024, the 2024-25 updated vaccine from Novavax was available.
• The original COVID-19 and 2022-23 bivalent vaccines are no longer commercially available.
• On June 27, 2024, the CDC adopted ACIP recommendations for all patients 6 months and older to receive an updated COVID-19 2024-25 vaccine. These vaccines are currently available for use.